Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCLL.L Regulatory News (CLL)

  • There is currently no data for CLL

Year end trading update

19 Jan 2009 07:00

RNS Number : 8037L
Cello Group plc
19 January 2009
 



19 January 2009

  

Cello Group plc

Year end trading update

 

Cello Group plc ("Cello" or the "Group", AIM: CLL), the leading independent market research and consulting group, today provides the following trading update for the year ended 31 December 2008

 

Since the announcement of the Group's interim results in early September, trading has tightened across certain sectors of Cello's broad domestic and international client base As a result, the Board anticipates that the Group's results for the full year will be at the lower end of market expectations.

There has been very strong cash conversion in the second half of 2008, as a result of which the Board expects to report year end net debt of less than £10.5m, significantly below consensus expectations.

The Group has agreed enlarged banking facilities with the revolving credit facility now increased from £18.0m to £20.0m for 2009, amortising to £17.0m for 2010. The overdraft facility of £2.0m has also been renewed and is now a multi-currency arrangement. The extra interest cost associated with these changes is expected to be broadly offset by lower overall interest rates.

The Group has re-estimated its total anticipated earn out obligations. These are now expected to be £15.2m compared with a previous estimate of £19.2m, with a minimum loan note component of £6.3m and the balance of £8.9m payable in shares. £7.8m of this total is anticipated to be settled in May 2009 with £3.2m payable in loan notes and £4.6m payable in shares. The balance of the total earn out commitment is payable between 2010 and 2013, with a loan note payment of £0.6m expected to be paid in 2010. The Group is entitled to pay an increased proportion of these total obligations in loan notes.

As well as the strong operating cash position and the reduced earn out provisions, the Group has continued to prudently reduce its cost base. In total over £2.0m of staff costs, on an annualised basis, have been removed during 2008.

Allan Rich, whose appointment as Acting Non-Executive Chairman was announced on September 2008has been confirmed as Non-Executive Chairman. Allan brings with him a wealth of experience of managing successfully through economic downturns.

 

The Group remains realistically cautious about the current outlook. While it is too early to give detailed guidance, numerous clients have indicated their intention to maintain their expenditure levels and the Group is seeing refreshed levels of spend from several of its public sector clients. In addition, all of Cello's investment start-up businesses are now trading profitably. All these factors, including the Group's strong financial position, should hold the Group in good stead in the current economic environment.

 

Cello expects to announce its preliminary results for the year ended 31 December 2008 on Tuesday 17 March 2009.

 

Enquiries

 

Cello Group 

 

Mark ScottChief Executive

020 7812 8460

Mark Bentley, Finance Director

 

Singer Capital Markets

 

Nicholas How

020 3205 7620

 

 

College Hill

 

Adrian Duffield/Rozi Morris

020 7457 2020

 

 

Notes to Editors (www.cellogroup.co.uk)

 

Cello is a market research and consulting group that listed on AIM in November 2004.

 

The Group's strategy is to create value for shareholders by building a world class market research business and a leading direct response business.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCGUUACGUPBGAQ
Date   Source Headline
2nd Oct 20198:40 amRNSDisposal
18th Sep 20197:00 amRNSInterim Results
23rd Aug 201910:40 amRNSHolding(s) in Company
16th Aug 20197:00 amRNSAcquisition of ISS
6th Aug 20193:07 pmRNSTotal Voting Rights
6th Aug 20197:00 amRNSNotification of Half Year Results
18th Jul 20197:00 amRNSPre-close Trading Update
20th Jun 20194:29 pmRNSDirector/PDMR Shareholding
10th Jun 20199:41 amRNSTotal Voting Rights
24th May 201912:45 pmRNSBlock listing Interim Review
20th May 20194:29 pmRNSIssue of Equity
15th May 20197:00 amRNSHolding(s) in Company
8th May 20191:30 pmRNSResult of AGM
8th May 20197:00 amRNSAGM Statement
1st May 201912:15 pmRNSTotal Voting Rights
15th Apr 201911:12 amRNSAnnual Report and Notice of AGM
10th Apr 20197:00 amRNSCapital Markets Event
4th Apr 201910:00 amRNSTotal Voting Rights
27th Mar 20191:00 pmRNSHolding(s) in Company
21st Mar 20193:10 pmRNSDirector/PDMR Shareholding
21st Mar 20197:00 amRNSPreliminary Results
6th Mar 20191:51 pmRNSHolding(s) in Company
7th Feb 20197:00 amRNSNotice of Full Year Results
17th Jan 20197:00 amRNSPre-Close Trading Statement
14th Dec 20189:24 amRNSBlock Listing Update
23rd Nov 20183:45 pmRNSHolding(s) in Company
19th Nov 20182:45 pmRNSHolding(s) in Company
12th Nov 201811:30 amRNSDirectorate Change
5th Nov 20182:00 pmRNSDirectorate Change
31st Oct 20183:30 pmRNSDirector/PDMR Shareholding
10th Oct 20187:00 amRNSDirector/PDMR Shareholding
2nd Oct 20187:00 amRNSAppointment of Executive Director
25th Sep 20181:00 pmRNSDirector/PDMR Shareholding
25th Sep 20187:00 amRNSDirector/PDMR Shareholding
24th Sep 201811:39 amRNSTransfer of FTSE classification to Healthcare
21st Sep 201810:15 amRNSDirector/PDMR Shareholding
20th Sep 20184:00 pmRNSHolding(s) in Company
20th Sep 20187:00 amRNSDirector/PDMR Shareholding
19th Sep 20187:00 amRNSInterim Results
22nd Aug 20181:51 pmRNSHolding(s) in Company
17th Aug 20187:00 amRNSNotification of Half Year Results
16th Aug 20182:00 pmRNSTotal Voting Rights
16th Aug 20181:30 pmRNSBoard Changes
23rd Jul 20187:00 amRNSHolding(s) in Company
19th Jul 20187:00 amRNSPre-close Trading Update
17th Jul 20187:00 amRNSChange of registered office
4th Jul 20181:53 pmRNSHolding(s) in Company
27th Jun 201812:46 pmRNSHolding(s) in Company
22nd Jun 20184:47 pmRNSHolding(s) in Company
20th Jun 20182:25 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.